CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
MAILPAN is developing a bioartificial pancreas to treat type 1 diabetes. The project focuses on enhancing the survival of pancreatic islets within the device and aims to advance the prototype through pre-clinical and clinical phases for eventual commercialization.
MAILPAN (MAcroencapsulation of PANcreatic Islets) is a prototype of bioartificial pancreas usable in the human designed to treat type 1 diabetic patients.
The prototype was developed along different stages since 1996 and led to the creation of the SME called Defymed in 2011.
Next step is now to bring the prototype to the pre-clinical and clinical phases necessary to the ensuing commercialization of MAILPAN whose ultimate goal is to improve the life of at least 20 million persons in the world whi…
CENTRE EUROPEEN D'ETUDE DU DIABETE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Ayr
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER
France, Montpellier
Type: Research institute
Activity type: Research Organisations
SME: No
United Kingdom, Oxford
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Strasbourg
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
